Cellular factors involved in the induction of resistance of HIV to antiretroviral agents

International Journal of Antimicrobial Agents

Volumn 16, Issue 3, 2000, Pages 353-356

  Turriziani, O ^a   Antonelli, G ^a   Dianzani, F ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Cellular kinase; Drug resistance; HIV; P glycoprotein

Indexed keywords

ANTIRETROVIRUS AGENT; GLYCOPROTEIN P; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; THYMIDINE KINASE; ZIDOVUDINE;

ANTIBIOTIC SENSITIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CHEMOTHERAPY; DRUG PROTEIN BINDING; ENZYME ACTIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT FAILURE; VIRUS MUTANT; VIRUS MUTATION;

ANTI-HIV AGENTS; DRUG RESISTANCE, MICROBIAL; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; NUCLEOSIDES; P-GLYCOPROTEIN; THYMIDINE KINASE;

EID: 0033737468     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(00)00264-8     Document Type: Article

References (35)

1. RNA virus populations as quasispecies
2. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase
3. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
4. Viral dynamics in human immunodeficiency virus type 1 infection
5. A working hypothesis - Virus resistance development as an indicator of specific antiviral activity
6. The pharmacokinetics of combination therapy with nelfinavir plus nevirapine
7. Mutation in retroviral genes associated with drug resistance
8. HIV treatment failure: Testing for HIV resistance in clinical practice
9. Viral and cellular factors for resistance against antiretroviral agents
10. Introduction of HIV drug-resistance testing in clinical practice
11. Resistance to HIV to antiretroviral agents. Basic concepts
12. Purification of P-glycoprotein from plasma membrane vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability
13. Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblasts
14. Mechanism of multidrug resistance
15. Clinical studies with modulators of multidrug resistance
16. Long-term exposure to zidovudine affects in vitro and in vivo the efficiency of phosphorylation of thymidine kinase
17. Evidence of in vitro development of drug resistance to azidothymidine in T-lymphotropic leukemia cell line (jurkat E6-1/AZT-100) and in pediatric patients with HIV-1 infection
18. 2',3'-Dideoxycytidine metabolism in a new drug-resistant cell line
19. The drug transporter P-glycoprotein limits oral adsorbtion and brain entry of HIV-1 proteinase inhibitors
20. HIV-1 proteinase inhibitor are substrate for the MDR1 multidrug transporter
21. Interaction of anti-HIV proteinase inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells
22. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors
23. Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with the human immunodeficiency virus reverse transcriptase
24. Biochemical pharmacology of zidovudine (AZT) in human T-lymphotropic cell (CEM)
25. Celluar thymidine kinase activity is required for the inhibition of HIV-1 replication by AZT in lymphocytes
26. Zidovudine induces the expression of cellular resistance affecting its antiviral activity
27. Cellular pharmacology of 2',3'-dideoxy-2',3'-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus
28. Cellular pharmacology of 2'-3'-didehydro-3'-deoxy-thymidine (d4T) in human peripheral blood mononuclear cells
29. Human immunodeficiency virus protease inhibitor serve as substrate for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters
30. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues
31. Abnormal expression of a 170-kD P-glycoprotein encoded by MDR1 gene, a metabolically active efflux pump, in CD4+ and CD8+ cells from patients with human immunodeficiency virus type 1 infection
32. Intracellular expression of P-170 glycoprotein in peripheral blood mononuclear cell subsets from healthy donors and HIV-infected patients
33. Resistance of HIV-1 to AZT might also involve the cellular expression of multidrug resistance P-glycoprotein
34. Cross-resistance to anti. HIV nucleoside analogues in multidrug-resistant human cells
35. May the drug transporter P-glycoprotein affect the antiviral activity of human immunodeficiency virus type 1 proteinase inhibitors?